热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　里昂发布研报称，翰森制药（03692）上半年业绩胜预期，收入同比增长12%，尽管监管环境严峻，报告/基础净利（剔除一次性收益）分别同比上升36%/19%。管理层重申2026年收入双位数增长指引，涵盖产品销售及BD收入。该行对公司全球扩张及2027年后新产品周期保持乐观，将目标价由42港元上调至43.7港元，并重申“跑赢大市”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.